Posted by Michael Wonder on 01 Jul 2021
Lupin announces FDA approval of supplemental new drug application for Solosec (secnidazole) for the treatment of trichomoniasis
1 July 2021 - Solosec demonstrated a 92.2% clinically and statistically significant cure rate for patients with trichomoniasis based on a landmark Phase 3 clinical trial.
Lupin Pharmaceuticals announced today that the U.S. FDA has approved the company's supplemental new drug application to expand the use of Solosec (secnidazole) to include the treatment of trichomoniasis in adults.
